Stage 3 uterine cancer is a serious diagnosis, but it is far from a death sentence. Five-year survival for women with stage 3 disease ranges from roughly 35% to 80%, a span so wide it almost seems like a different disease at each end. The enormous variation comes down to the specific type of cancer cell involved, its molecular profile, how successfully surgery removes visible tumor, and whether newer treatments like immunotherapy apply. Understanding where you or a loved one falls within that range matters more than the stage number alone.
What Stage 3 Means in Practice
Stage 3 uterine cancer means the disease has grown beyond the uterus itself but has not spread to distant organs like the lungs or liver. That distinguishes it from stage 4, where distant metastasis has occurred, and from stages 1 and 2, where the cancer remains confined to the uterus or cervix. Within stage 3, the 2023 FIGO staging system breaks things down further. Stage IIIA involves spread to the ovaries or fallopian tubes or to the outer surface of the uterus. Stage IIIB means the cancer has reached the vagina, the tissue alongside the uterus, or the pelvic lining. Stage IIIC involves lymph node metastasis, with distinctions made between pelvic and para-aortic nodes and between tiny deposits versus larger ones.1PubMed. FIGO staging of endometrial cancer: 2023
These substages are not just academic bookkeeping. A woman with stage IIIA disease where the cancer has reached one ovary faces a different treatment plan and a different prognosis than a woman with stage IIIC disease involving multiple enlarged para-aortic lymph nodes. When doctors talk about “stage 3,” they are really describing a broad corridor of disease severity, and the substage refines the picture considerably.
Survival Rates Vary Dramatically by Cell Type
The single most important factor driving survival within stage 3 is the histological subtype, meaning the kind of cancer cell under the microscope. A large national database analysis of over 28,000 stage 3 patients found five-year overall survival of about 80% for low-grade endometrioid cancers, dropping to around 50% for high-grade endometrioid tumors, roughly 40% for clear cell carcinomas, and about 36% for uterine papillary serous carcinomas.2PubMed. Survival Differences Among Uterine Papillary Serous, Clear Cell and Grade 3 Endometrioid Adenocarcinoma Endometrial Cancers: A National Cancer Database Analysis That is a gap of more than 40 percentage points between the best and worst cell types, all within the same stage.
Serous carcinomas are especially aggressive. A separate study comparing high-grade endometrioid cancers directly to serous tumors found that women whose tumors were predominantly serous had a five-year survival of about 41%, compared with 75% for high-grade endometrioid disease. Serous tumors were also more than twice as likely to have already spread beyond the uterus at diagnosis.3PubMed. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? If your pathology report identifies a serous component, treatment tends to be more aggressive from the outset.
Molecular Profiling Adds Another Layer
Over the past decade, researchers have discovered that endometrial cancers can be sorted into molecular subgroups that predict behavior independently of what the cells look like under a microscope. The four main groups are POLE-mutated, mismatch repair deficient (often called dMMR), no specific molecular profile (NSMP), and p53-abnormal. A recent study found overall survival of 100% in the POLE-mutated group, about 85% in the NSMP group, roughly 78% in dMMR tumors, and around 65% in p53-abnormal tumors.4PubMed Central. Association of Molecular Classification with FIGO Stage and Survival Outcomes in Endometrial Cancer
This molecular information is increasingly used to guide treatment decisions. A tumor that looks aggressive under the microscope but carries a POLE mutation may actually have an excellent prognosis, while a p53-abnormal tumor that seems moderate-grade may behave much worse than expected. For stage 3 patients, molecular subtyping is particularly relevant because it can determine eligibility for immunotherapy, which has transformed outcomes for certain subgroups.
Why Surgery Remains the Starting Point
For most women with stage 3 uterine cancer, treatment begins with surgery. The goal is a hysterectomy with removal of the ovaries, fallopian tubes, and as much visible tumor as possible. When the cancer has spread to the pelvic lining, the procedure resembles the kind of debulking surgery used in ovarian cancer. Whether the surgeon can remove all visible disease turns out to be one of the strongest predictors of how long a patient lives.
A meta-analysis of patients who underwent debulking surgery for advanced endometrial cancer found that those with no visible residual tumor afterward had a median progression-free survival of about 19 months, compared with roughly 6 months for women who still had visible disease remaining. Overall survival showed a similar pattern: about 41 months versus 21 months.5PubMed Central. Primary or Interval Debulking Surgery for Advanced Endometrial Cancer with Carcinosis: A Systematic Review and Individual Patient Data Meta-Analysis of Survival Outcomes A separate retrospective study confirmed the picture, reporting that patients with no residual disease had median overall survival of 25 months versus 13 months for those with gross residual tumor, and that having leftover disease roughly doubled the risk of death on multivariate analysis.6International Journal of Surgery. Survival impact of cytoreduction to microscopic disease for advanced stage cancer of the uterine corpus: A retrospective cohort study
The practical takeaway is that the experience and aggressiveness of the surgical team matters. If complete removal of visible disease is achievable, the survival benefit is substantial. In cases where the cancer is too widespread for upfront surgery, some patients receive chemotherapy first to shrink the disease before attempting debulking.
Chemotherapy, Radiation, and the Question of Combining Them
After surgery, most women with stage 3 uterine cancer receive some form of adjuvant therapy. The standard backbone is carboplatin and paclitaxel chemotherapy, which has strong evidence for patients with stage IIIC disease involving positive lymph nodes.7PubMed Central. Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings Radiation therapy, including external beam treatment to the pelvis and sometimes vaginal brachytherapy, is the other pillar.
A major question has been whether combining chemotherapy with radiation is better than chemotherapy alone. A landmark New England Journal of Medicine trial (known as GOG-258) tackled this directly. At five years, about 59% of patients receiving chemoradiation were alive and relapse-free, compared with 58% in the chemotherapy-only group. The combination did reduce local recurrences in the pelvis and lymph nodes substantially, but it was offset by a higher rate of distant recurrences. The net result: no improvement in overall relapse-free survival with the addition of radiation to chemotherapy.8PubMed Central. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
That does not mean radiation has no role. A large database study found that adding vaginal brachytherapy to either chemotherapy alone or combination chemoradiation was associated with a reduced risk of death.9PubMed Central. Chemotherapy, Radiation, or Combination Therapy for Stage III Uterine Cancer The nuance matters: brachytherapy is a focused, localized treatment that helps prevent cancer from recurring at the top of the vagina, a common site of relapse. For many patients, the current approach is chemotherapy with the selective addition of radiation based on the specific pattern of disease spread.
Immunotherapy Has Changed the Game for Some Patients
The most exciting development in uterine cancer treatment over the past few years has been immunotherapy, particularly for tumors with mismatch repair deficiency. These dMMR tumors have a high number of genetic mutations, which makes them more visible to the immune system when given a checkpoint inhibitor.
In the NRG-GY018 trial, adding pembrolizumab to standard chemotherapy for advanced or recurrent endometrial cancer produced striking results in the dMMR subgroup. At 12 months, about 74% of patients in the pembrolizumab group were alive without disease progression, compared with 38% in the placebo group. That translated to a 70% reduction in the relative risk of progression or death.10PubMed Central. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer Dostarlimab, another checkpoint inhibitor, received expanded FDA approval in 2024 for use with chemotherapy in endometrial cancer.11PubMed Central. Clinical Use of Dostarlimab in Advanced Stage and Recurrent Endometrial Cancer: Patient Selection and Perspectives In dMMR recurrent or advanced endometrial cancer, dostarlimab showed an overall response rate of about 42%, with responses lasting a median of nearly 35 months.12PubMed Central. Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer
For the roughly quarter of endometrial cancers that are dMMR, immunotherapy has genuinely rewritten the prognosis. For women whose tumors do not have this feature, immunotherapy is less effective, and clinical trials are exploring other approaches. One such avenue is trastuzumab for HER2-positive uterine serous carcinomas. A clinical trial of 58 women with this specific subtype found that adding trastuzumab to standard chemotherapy extended median progression-free survival from 8 to 13 months and overall survival from about 24 to 30 months.13PubMed Central. Trastuzumab May Improve Survival in Women with Rare Endometrial Cancer These are incremental but meaningful gains for a particularly aggressive cancer type.
Where and How Stage 3 Uterine Cancer Tends to Recur
Even with aggressive treatment, recurrence remains a significant concern. The most common sites for recurrence include the pelvis, pelvic and para-aortic lymph nodes, the peritoneal lining of the abdomen, and the lungs. Less frequently, recurrence can appear in the liver, bones, brain, or distant lymph nodes outside the abdomen.14PubMed Central. Typical and atypical metastatic sites of recurrent endometrial carcinoma
Recurrence patterns also differ by molecular subtype. Tumors with mismatch repair deficiency tend to recur locally, often in the pelvis, where they may be treatable with radiation or surgery. P53-abnormal tumors are more likely to recur throughout the abdomen. Among NSMP and POLE-mutated cancers, when recurrence does happen, it tends to appear at distant sites.15Gynecologic Oncology. Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification Knowing where recurrence is most likely to show up helps oncologists tailor surveillance. A woman with a dMMR tumor may benefit from more frequent pelvic imaging, while a woman with a p53-abnormal tumor may warrant closer monitoring for abdominal spread.
How Other Health Conditions Shape Outcomes
Uterine cancer is closely linked to obesity, and many women diagnosed with it carry additional health conditions like diabetes, hypertension, and cardiovascular disease. These comorbidities affect not just quality of life but survival itself. A study focused specifically on stage 3 endometrial cancer found that women with a high comorbidity burden had five-year overall survival of only about 23%, compared with 65% for women with few or no comorbidities. Higher comorbidity scores were also associated with lower rates of receiving adjuvant chemotherapy, potentially compounding the problem.16PubMed. Does Age-Adjusted Charlson Comorbidity Score Impact Survival Endpoints in Women with Federation of Gynecology and Obstetrics-Stage III Endometrial Cancer?
The relationship between morbid obesity and outcomes has generated mixed findings. One study found that morbidly obese patients with endometrial cancer had a roughly 2.7-fold increased risk of death compared with obese patients whose body mass index was below 40.17PubMed Central. The impact of morbid obesity on survival of endometrial cancer However, a separate analysis using propensity-weighted methods found no significant difference in progression-free or overall survival between morbidly obese and non-morbidly-obese patients, though morbidly obese women were less likely to undergo lymph node removal during surgery, potentially affecting staging accuracy.18European Journal of Gynaecological Oncology. Treatment outcomes and survival in morbidly obese women with endometrial cancer The disagreement in the literature likely reflects differences in how well comorbidities were controlled and how aggressively each group was treated. What does seem clear is that morbid obesity can make it harder to receive optimal surgical staging and treatment, which indirectly affects outcomes.
Racial Disparities That Persist Even in Equal-Access Systems
Black women diagnosed with endometrial cancer have consistently worse survival outcomes than white women, and part of that gap is explained by a higher proportion of aggressive subtypes like serous carcinoma. But biology alone does not account for the full difference. A study conducted within an equal-access healthcare system, where insurance and ability to pay should not be factors, found that non-Hispanic Black women had a 64% higher adjusted risk of death compared with non-Hispanic white women, even after controlling for age, stage, tumor type, grade, and treatment received. Among women with low-grade endometrioid carcinomas, where survival is generally favorable, Black women still had about 2.5 times the risk of death.19PubMed Central. Racial Disparities in Survival among Women with Endometrial Cancer in an Equal Access System
These findings point toward factors beyond tumor biology and treatment access, potentially including differences in tumor biology not captured by standard pathology, delays in symptom recognition, or unmeasured environmental and social stressors. For Black women with stage 3 disease, awareness of this disparity is important, and seeking care at high-volume cancer centers with multidisciplinary teams may help close the gap.
Treatment Side Effects and Long-Term Quality of Life
Stage 3 treatment is aggressive, and the side effects reflect that. Lymphedema, the swelling that can develop when lymph nodes are removed or damaged by radiation, is one of the most persistent problems. A study tracking endometrial cancer patients over five years found that numbness, aching, and poor physical function were reported by more than half of patients at the initial survey, and the majority of those symptoms persisted at the five-year follow-up. Among patients who completed both surveys, about 70% still experienced poor physical function and numbness years after treatment.20PubMed Central. The frequency and persistence of lymphedema diagnosis and self-reported symptoms over 5 years in patients with endometrial carcinoma
There is a more encouraging side of the picture, though. A prospective study that measured quality of life before treatment and six months after surgery found meaningful improvements across multiple dimensions: physical functioning, psychological well-being, overall health, and perceived stress all improved. Advanced-stage patients actually showed larger reductions in stress than early-stage patients, likely because the completion of treatment brought particular psychological relief.21PubMed Central. Quality-of-Life Trajectories and Perceived Stress in Women Treated for Uterine Cancer: A Six-Month Prospective Study The point is that while long-term side effects are real, the trajectory for most women is one of gradual recovery, not steady decline.
Menopause After Treatment
Because treatment for stage 3 uterine cancer almost always includes removal of both ovaries, women who have not already gone through menopause will experience sudden surgical menopause. The symptoms can be severe: hot flashes, sleep disruption, vaginal dryness, mood changes, and accelerated bone loss. For women with early-stage, low-risk endometrial cancer, hormone replacement therapy is sometimes considered. But for stage 3 or high-risk histological subtypes like serous or clear cell carcinoma, hormone replacement is generally considered contraindicated due to concern about fueling a recurrence.22healthbook TIMES Oncology Hematology. Hormone Replacement Therapy After Endometrial Cancer: Current Evidence and Treatment Recommendations
That leaves non-hormonal options for managing menopausal symptoms: SSRIs and SNRIs for hot flashes, vaginal moisturizers for dryness, weight-bearing exercise and sometimes bisphosphonates for bone health, and cognitive behavioral therapy for sleep disruption. These alternatives are less effective than hormone replacement for some symptoms, but they are the options available when hormonal therapy carries too much risk. Having a frank conversation with your oncologist about which symptoms are most disruptive can help prioritize management strategies.
How Accurate Is the Staging Itself
One underappreciated issue is that staging depends partly on imaging, and imaging is not perfect. Final staging happens after surgery, when a pathologist examines the removed tissue and lymph nodes. But preoperative imaging guides surgical planning and helps set expectations. A study comparing PET/MRI to PET/CT in endometrial cancer found that PET/MRI was more accurate for assessing how deeply the cancer had invaded the uterine wall, with an accuracy of 93% versus about 74% for PET/CT. Both modalities performed similarly for detecting pelvic lymph node involvement, with accuracy around 95%.23PubMed Central. Diagnostic value of integrated 18 F-FDG PET/MRI for staging of endometrial carcinoma: comparison with PET/CT
For practical purposes, preoperative imaging gives a reasonable approximation, but it can underestimate or overestimate the extent of disease. A woman told she has stage 3 cancer based on imaging may be upstaged to stage 4 or downstaged to stage 2 once surgical pathology is complete. This uncertainty is worth keeping in mind when processing an initial diagnosis: the stage written on the imaging report is a best estimate, not the final word.